bioMrieux, lder worldwide in the field of in vitro diagnostics, has launched NucliSENS EasyQ HPV, a molecular diagnostics test for human papillomavirus deteccin used in the prevention of c cervical cancer.
The neck cncer uterus is one of the leading causes of death among women in the development passes you, and in addition, is the second type of common cncer ms worldwide. Every year 250,000 ms muertes.1 causes human papillomavirus, or HPV, is responsible for 99.7% of cases of uterino.2 neck cncer Numerous investigations have demonstrated that genotypes 16 and 18 cause about 70% of uterus neck cnceres HPV-induced wide world.3
In most cases, infection by HPV is transient. However, in 20% of women may have a persistent and cause injury carcter cervical (neck of the uterus). Of 1 to 10% of these lesions may develop into a cancer of crvix. It is therefore very important to identify clearly and early the infeccin in women who are at high risk of developing this type of cancer.
The tcnico of molecular diagnostics for HPV deteccin are used in screening patients with suspected precancerous cervical lesions.
These methods, described, along with anlisis citolgicos (crvico-vaginal smear), help determine a qu women, those with abnormal results citolgicos (ASCUS *), they must guide immediately to biopsy and tratamiento.4
The majority of the current HPV molecular tests allow deteccin-DNA-virus genome in cervical cells;. However, the positive test result indicates a infeccin only HPV, whether transient or persistent. These tests do not eval oncognica virus activity, ie its potential to cause cancer.
It is known that after the integration of the viral genome into the genome of the cells cervical Husped occurs expresin PROTEIN oncognicas the persistent viral E6 and E7.
This involves expresin abnormal modificacin cell cycle, leading to an increased cellular proliferacin, starting as a process of malignizacin from the cervix. Indeed, this seal represents an early marker of cncer.5
Reported by various publications, 6,7,8 of the deteccin The expression of oncogenes E6/E7 (mRNA level) est closely linked to the presence of high grade precancerous lesions in women who have a type cytology ASCUS / LSIL **. That is why this type of experiment is ms-Specific, and has great value in health surveillance methods, described comparacin with deteccin based on DNA. As the results immediately orient patients to undergo a colposcopy, significantly decreasing the number of invasive examinations Intil (biopsies, other colposcopy) .9
* ASCUS: squamous cells; atpicas of undetermined significance
** LSIL: squamous intraepithelial lesions of low grade
EasyQ NucliSENS HPV tests are based on an innovative concept that detects The expression of risk factors oncognicos E6 and E7 in 5 ms frequent HPV types for this type of Cancer (HPV 16, 18, 31, 33 and 45). Thanks to this-Specific diagnostics, the new method offers professionals a valuable health surveillance test, which can improve significantly the attention of patients.
Recognizing the value of the evidence clinician for deteccin of E6/E7 mRNA rpidamente expands its proof is in incorporacin recent Danish national recommendations for the diagnostics of neck cncer of uterus.
References:
1. WHO website referred pages / NCCC websites
2. Walboomers, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.J. Pathol. 1999, 189: 12-19
3. Kahn et al., The elevated 10-year risk of high risk of cervical cancer in women with HPV type 16 or 18. J. Nat Cancer Inst 2005, Vol 97, n 14
4. Wright TC, Schiffman M, Solomon D et al., Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004; 103:304-309
5. Zur Hausen et al. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2: 342-50.
6. Lie et al., DNA-versus RNA-based methods for HPV detection in cervical neoplasia. Gynec. Onc. 2005, 97: 908-915
7. Molden et al., Comparison of HPV mRNA and DNA detection: a cross-sectional study of 4136 women> 30 years of age with a 2-years follow-up of high grade squamous intraepithelial lesion. Int J. Cancer 2005; 114: 973-976
8. Cuschieri et al., HPV type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J. Virol.2004 Med, 73: 65-70
9. Molden et al., Predicting CIN2 + when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year Follow-up of women with ASCUS or LSIL Pap smear. Int J. Cancer 2005; 114: 973-976
10. Screening for Cervical Cancer. Sundhedsstyrelsen, Denmark, 2007
About bioMrieux, lder worldwide in the field of in vitro diagnostics for 45 years, bioMrieux est present in 150 ms travs passes of 39 subsidiaries and a extensive network of distributors. In 2007, the volume totaled bioMrieux facturacin of 1 063 million, of which 84% corresponds to its international activity.
bioMrieux offers diagnostics solutions (reagents, instruments and software) which determine the source of a disease or contaminacin to improve patient health and ensure consumer safety. BioMrieux products are used in the diagnostics of infectious diseases and provide health surveillance valuable results for cardiovascular emergencies and the diagnostics and monitoring of cancer. Also used for deteccin microorganisms in agri-food products and cosmetics farmacuticos.
bioMrieux is a company listed on NYSE Euronext Paris. (Cdigo: BIM - Cdigo ISIN: FR0010096479).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment